Clinical trial
A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT04210375 is registered in ClinicalTrials.gov with Salubris Biotherapeutics Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
- Lead sponsor
- Salubris Biotherapeutics Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 21, 2020
- Completion date
- July 7, 2023
- Enrollment
- 14 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
heart failure with reduced ejection fraction